Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc.
Your view on AUPH
Overview
What the company does, where it operates, and who runs it.
About Aurinia Pharmaceuticals Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Peter S. Greenleaf
- Headquarters
- 4464 Markham Street, Edmonton, BC, CA
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Peter S. Greenleaf
- Headquarters
- 4464 Markham Street, Edmonton, BC, CA
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Infographics
Visual summary of the business at a glance.
Media
Videos and interviews covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Comparables
List of peer companies in the same industry.
Institutional Ownership
Which funds and firms own the stock.
Insider Trading
Recent buying and selling by company executives.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
News
Latest headlines and market coverage.